Join the Metadate CD group to help and get support from people like you.
Metadate CD News
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
WEDNESDAY, July 2, 2025 – The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 – Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations...
FDA Medwatch Alert: FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD
FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated...
Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
TUESDAY, June 17, 2025 – Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder...
ADHD Stimulants Can Be Safely Prescribed Via Telehealth, Study Argues
MONDAY, June 16, 2025 — People with ADHD might be prescribed their meds remotely without increasing their risk of addiction, a new study says. Experts have worried that prescribing stimulants like A...
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...
ADHD Drugs Generally Safe For Heart Health, Review Says
MONDAY, April 14, 2025 – Worried about taking the ADHD meds you’ve been prescribed because they might harm your heart health? There’s no need to fret, according to a new evidence review. ADHD med...
Big Drop in U.S. Kids, Teens Misusing Prescription Meds
WEDNESDAY, July 24, 2024 – Misuse of illicit prescription drugs is falling dramatically among U.S. high school students, a new study says. The percentage of seniors who say they’ve misused p...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
FDA Medwatch Alert: Methylphenidate ADHD Medications: Drug Safety Communication - Risk of Long-lasting Erections
ISSUE: FDA is warning that methylphenidate products (including Concerta, Daytrana, Focalin/Focalin XR, Metadate CD/Metadate ER, Methylin/Methylin ER, Quillivant XR, Ritalin/Ritalin LA/Ritalin SR),...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD)